EFNA3 and invasive breast carcinoma: To assess and validate LRRC15, EFNA3, TSPAN13, and CA12 in terms of the protein level, immunohistochemistry (IHC) was performed on TMA slides containing 100 cases of invasive breast carcinomas, nine adjacent non-tumor breast tissue samples, and one adjacent breast tumor tissue sample, along with clinicopathological features.